Details for Patent: 8,268,847
✉ Email this page to a colleague
Which drugs does patent 8,268,847 protect, and when does it expire?
Patent 8,268,847 protects OPSUMIT and OPSYNVI and is included in two NDAs.
Protection for OPSUMIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-one patent family members in thirty-three countries.
Summary for Patent: 8,268,847
| Title: | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
| Abstract: | The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. |
| Inventor(s): | Martine Clozel |
| Assignee: | Actelion Pharmaceuticals Ltd |
| Application Number: | US12/439,290 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,268,847 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,268,847
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion | OPSUMIT | macitentan | TABLET;ORAL | 204410-001 | Oct 18, 2013 | AB | RX | Yes | Yes | 8,268,847*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Actelion | OPSYNVI | macitentan; tadalafil | TABLET;ORAL | 218490-001 | Mar 22, 2024 | RX | Yes | No | 8,268,847*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Actelion | OPSYNVI | macitentan; tadalafil | TABLET;ORAL | 218490-002 | Mar 22, 2024 | RX | Yes | Yes | 8,268,847*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,268,847
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/IB2006/052999 | Aug 29, 2006 | |
| PCT/IB2006/053857 | Oct 19, 2006 | |
| PCT Information | |||
| PCT Filed | August 28, 2007 | PCT Application Number: | PCT/IB2007/053448 |
| PCT Publication Date: | March 06, 2008 | PCT Publication Number: | WO2008/026156 |
International Family Members for US Patent 8,268,847
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2059246 | ⤷ Start Trial | CA 2024 00050 | Denmark | ⤷ Start Trial |
| European Patent Office | 2059246 | ⤷ Start Trial | PA2024537 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2059246 | ⤷ Start Trial | 301308 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2059246 | ⤷ Start Trial | LUC00371 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2059246 | ⤷ Start Trial | 122024000070 | Germany | ⤷ Start Trial |
| European Patent Office | 2059246 | ⤷ Start Trial | 45/2024 | Austria | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
